GLP-1 Agonist Therapy Center

Patients who have obesity but don't have diabetes may now reap the benefits of using a GLP-1 receptor agonist.

Can a new potential treatment combining an SGLT-2 and a GLP-1 RA mitigate cardiometabolic risk?

Contrary to previous studies, new research finds SGLT-2i more effective for weight loss than GLP-1 RAs as add-on therapy to Metformin. 

With the introduction of this glucagon-like peptide-1 receptor agonist (GLP-1 RA), efpeglenatide, could we see new cardiovascular and renal benefits for patients with type 2 diabetes?

American Diabetes Association symposium presents new phase 3 clinical trials of SURPASS-3 and SURPASS-5. 

The GRADE Study is the most comprehensive study comparing multiple diabetic medications to assess efficacy in type 2 diabetes. So which drug therapy reigned supreme?

The study evaluates the healthcare cost associated with two principal therapies for patients with type 2 diabetes.  

Results for SURPASS-1 and SURPASS-2 trials of tirzepatide in patients with type 2 diabetes inadequately controlled with diet and exercise alone were presented at this year’s virtual symposium. If you weren’t able to attend the symposium, you can read about the trials here. 

How do the effectiveness and safety of long-acting GLP-1 RAs compare to short-acting GLP-1 RAs, when paired with basal insulin? 

How important is GLP-1 RA effect on Hemoglobin A1c reduction in determining cardiovascular risk?